# FUSCC Refractory TNBC Platform Study (FUTURE2.0)

> **NCT05749588** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 120 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** A1: SHR-A1811
- **DRUG:** A2: SHR-A1811 with Camrelizumab with famitinib
- **DRUG:** B1: TROP2 ADC
- **DRUG:** B2: TROP2 ADC with Camrelizumab
- **DRUG:** C1: SHR-A1811
- **DRUG:** C2: SHR-A1811 with BP102
- **DRUG:** D1: TROP2 ADC
- **DRUG:** D2: TROP2 ADC with BP102
- **DRUG:** E1: SHR-A1811
- **DRUG:** F1: TROP2 ADC
- **DRUG:** G1: SHR-A1811
- **DRUG:** H1: TROP2 ADC
- **DRUG:** E2: SHR-A1811 with everolimus
- **DRUG:** TQB2102 with TQB2868

## Key facts

- **NCT ID:** NCT05749588
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749588, "FUSCC Refractory TNBC Platform Study (FUTURE2.0)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05749588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*